Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Recurrence 2Multiple Myeloma 2Lymphoma, B-Cell 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Congenital Abnormalities 1Burkitt Lymphoma 1

Interventions

Cytarabine 34Filgrastim 14Idarubicin 13Etoposide 12Busulfan 12fludarabine phosphate 10Peripheral Blood Stem Cell Transplantation 10Cyclophosphamide 10Mitoxantrone 8Methotrexate 7Daunorubicin 7Cyclosporine 6Tacrolimus 5Radiotherapy 5Clofarabine 5Whole-Body Irradiation 4Mycophenolic Acid 4Gemtuzumab 4Arsenic Trioxide 4Antilymphocyte Serum 4Topotecan 3Imatinib Mesylate 3Granulocyte Colony-Stimulating Factor 3Flow Cytometry 3Decitabine 3eltrombopag 2choline magnesium trisalicylate 2aldesleukin 2Vorinostat 2Thiotepa 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia, Myelomonocytic, Acute × Proteasome Inhibitors × Clear all
NCT02030405 2019-04-05

Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Stanford University

Phase 2 Terminated
4 enrolled 10 charts
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡